Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.

Original languageEnglish
Pages (from-to)65-69
Number of pages5
JournalJournal of Neuropsychiatry and Clinical Neurosciences
Volume19
Issue number1
DOIs
StatePublished - 1 Jan 2007

Fingerprint

alpha-Methyltyrosine
Dystonia
Dyskinesias
Tyrosine 3-Monooxygenase
Dopamine
Antipsychotic Agents
Pheochromocytoma
Down-Regulation
Phosphorylation
Enzymes

Cite this

@article{e943e153b04a474eade58aae363cf9bf,
title = "Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia",
abstract = "AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.",
author = "Ralph Ankenman and Salvatore, {Michael Francis}",
year = "2007",
month = "1",
day = "1",
doi = "10.1176/jnp.2007.19.1.65",
language = "English",
volume = "19",
pages = "65--69",
journal = "The Journal of neuropsychiatry and clinical neurosciences",
issn = "0895-0172",
publisher = "American Psychiatric Publishing Inc.",
number = "1",

}

Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia. / Ankenman, Ralph; Salvatore, Michael Francis.

In: Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 19, No. 1, 01.01.2007, p. 65-69.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia

AU - Ankenman, Ralph

AU - Salvatore, Michael Francis

PY - 2007/1/1

Y1 - 2007/1/1

N2 - AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.

AB - AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical settings, AMPT is approved to treat pheochromocytoma. Dystonias and dyskinesias seem to have their origin in inconsistent regulation of dopamine function in dopamine pathways. This paper presents case histories of the clinical efficacy of AMPT for treating certain individuals with neuroleptic-induced dystonia or dyskinesia. The authors propose that a special utility of AMPT in tardive disorders may be related to a downregulation of tyrosine hydroxylase activity that may be increased by neuroleptic-induced effects on tyrosine hydroxylase phosphorylation.

UR - http://www.scopus.com/inward/record.url?scp=33847103835&partnerID=8YFLogxK

U2 - 10.1176/jnp.2007.19.1.65

DO - 10.1176/jnp.2007.19.1.65

M3 - Article

VL - 19

SP - 65

EP - 69

JO - The Journal of neuropsychiatry and clinical neurosciences

JF - The Journal of neuropsychiatry and clinical neurosciences

SN - 0895-0172

IS - 1

ER -